Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.72 |
| ▸ | ALB | P02768 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784233 | 1.00 | TTR (0.72) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL1675290 | 0.97 | TTR (0.68) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL1675377 | 0.91 | TTR (0.68) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL1675531 | 0.88 | TTR (0.68) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL121973 | 0.88 | CASP3 (0.69) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL445014 | 0.88 | HDAC6 (0.74) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL28616672 | 0.87 | TTR (0.67) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL30485193 | 0.87 | TTR (0.67) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL20898024 | 0.87 | HDAC6 (0.74) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL20897612 | 0.87 | MAOA (0.80) | TTRALBMAOACNR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | claimed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | claimed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| CN-100448852-C | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2009-01-07 | — | — | CN | claimed |
| EP-1587821-B1 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2008-08-20 | — | — | EP | claimed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | claimed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | claimed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN-LA ROCHE INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| CN-1747965-A | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | TTR 1658/4885ALB 4666/4885MAOA 2586/4885 |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | TTR 1/4885ALB 26/4885MAOA 1980/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | TTR 4320/4885ALB 3280/4885MAOA 583/4885 |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, LIPC, PNLIP | TTR 4395/4885ALB 3361/4885MAOA 375/4885 |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | TTR 1658/4885ALB 4666/4885MAOA 2586/4885 |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | TTR 522/4885ALB 2374/4885MAOA 2578/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | TTR 1/4885ALB 10/4885MAOA 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.